Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has launched a long-term study to look at the effectiveness of its migraine medication, Emgality, in a real-world setting instead of a formal clinical trial.
The company says the objective of the study is to evaluate how the medication works compared to other preventative treatments for migraines.
Lilly says it will study migraine sufferers who routinely receive medical care and are switching to other prescription treatments.
“It’s been estimated that more than 40% of people who use migraine preventive treatments have a history of failure or switching,” said Gudarz Davar, M.D., vice president, neurology development, Lilly Bio-Medicines.
The company says it plans to enroll approximately 2,850 patients from multiple sites across the U.S., Europe, and Asia.
For two years, the study, named TRIUMPH, will track prescribing and treatment choices and the discontinued use of medications, including Emgality.
Lilly says the study will also examine reductions in monthly migraine headache days, acute medication outcomes and other patterns of migraine treatment use during the run of the study.
“By tracking physician and patient treatment decisions in the real world, the results from TRIUMPH will contribute to a more comprehensive understanding of the real-world benefit of Emgality and its comparative effectiveness as a long-term treatment option,” said Patrik Jonnson, senior vice president and president, Lilly Bio-Medicines.
Migraine is the second leading cause of disability in the U.S. and affects more than 30 million adults. Women are three times more likely to suffer from migraines than men in the U.S.